Comprehensive Review Illuminates Key Molecular Drivers and Therapeutic Targets in Osteoarthritis Pathogenesis
Background
Osteoarthritis (OA) is a debilitating degenerative joint disease affecting 595 million globally, characterized by progressive articular cartilage breakdown, subchondral bone changes, and chronic inflammation. Current treatments primarily manage symptoms, failing to halt disease progression due to its complex, multifactorial etiology. Understanding the intricate molecular mechanisms, including cytokines, adipokines, and enzymes, is crucial for identifying novel therapeutic targets and developing disease-modifying interventions.
Study Design
This critical overview systematically synthesizes current literature on the molecular pathophysiology of osteoarthritis (OA). The authors analyzed published research focusing on key molecular players implicated in OA progression, including various cytokines, RANKL, MMPs, adipokines, and phosphate dysregulation. The review aims to consolidate insights into these mechanisms to identify potential therapeutic targets.
Results
This critical overview synthesizes existing literature on osteoarthritis (OA), a condition affecting approximately 595 million people worldwide in 2020, representing 7.6% of the global population. The number of cases increased by 132.2% compared to 1990. The review highlights that knee OA is the most common site and contributor to the overall burden, with its age-standardized prevalence rate increasing between 1990 and 2019. > Hip OA prevalence was estimated at 8.55% (95% CI, 4.85–13.18) for Kellgren–Lawrence grade ≥ 2. While knee and hip OA share pathogenic mechanisms, the review notes their differences in prevalence, prognosis, biomechanics, and molecular pathophysiology, setting the stage for detailed molecular insights into these distinct conditions.
Key Findings
- Osteoarthritis (OA) affected 595 million people globally in 2020, representing 7.6% of the world population.
- Global OA cases increased by 132.2% from 1990 to 2020.
- Knee OA is the most prevalent form, with its age-standardized prevalence rate increasing between 1990 and 2019.
- Hip OA prevalence was estimated at 8.55% (95% CI, 4.85–13.18) for Kellgren–Lawrence grade ≥ 2.
- Review identifies cytokines,
RANKL,MMPs, adipokines, and phosphate dysregulation as key molecular drivers of OA.
Why It Matters
This comprehensive review provides a crucial consolidated resource for understanding the complex molecular underpinnings of osteoarthritis (OA). By systematically outlining key cytokines, enzymes, adipokines, and phosphate dysregulation, it offers a roadmap for identifying and validating novel therapeutic targets beyond symptomatic relief. This synthesis is vital for researchers and drug developers aiming to create disease-modifying OA drugs. For clinicians, it deepens understanding of OA's multifaceted nature, potentially informing future personalized treatment strategies as new molecularly targeted therapies emerge. It underscores the need for interventions that address specific molecular pathways rather than just managing pain.